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Abstract
The innate host response to virus infection is largely dominated by the production of type I interferon and interferon
stimulated genes. In particular, fibroblasts respond robustly to viral infection and to recognition of viral signatures such as
dsRNA with the rapid production of type I interferon; subsequently, fibroblasts are a key cell type in antiviral protection. We
recently found, however, that primary fibroblasts deficient for the production of interferon, interferon stimulated genes, and
other cytokines and chemokines mount a robust antiviral response against both DNA and RNA viruses following stimulation
with dsRNA. Nitric oxide is a chemical compound with pleiotropic functions; its production by phagocytes in response to
interferon-c is associated with antimicrobial activity. Here we show that in response to dsRNA, nitric oxide is rapidly
produced in primary fibroblasts. In the presence of an intact interferon system, nitric oxide plays a minor but significant role
in antiviral protection. However, in the absence of an interferon system, nitric oxide is critical for the protection against DNA
viruses. In primary fibroblasts, NF-kB and interferon regulatory factor 1 participate in the induction of inducible nitric oxide
synthase expression, which subsequently produces nitric oxide. As large DNA viruses encode multiple and diverse immune
modulators to disable the interferon system, it appears that the nitric oxide pathway serves as a secondary strategy to
protect the host against viral infection in key cell types, such as fibroblasts, that largely rely on the type I interferon system
for antiviral protection.
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Introduction
A central theme today in medical research is understanding the
delicate balance of interactions between a pathogen and its host.
These interactions dictate the pathological consequences of
infections. It is well recognized that the innate immune response
against pathogens focuses on detection of highly conserved
pathogen-associated molecular patterns (PAMPs) that are distinct
from the host. Host pathogen recognition receptors have evolved
to recognize patterns such as nucleic acids from pathogens
including bacteria and viruses [1]. The first line of defence against
invading pathogens is the rapid and robust production of type I
interferon (IFN), a family of cytokines with potent immune
stimulatory and pathogen-controlling properties. Fibroblasts are
amongst the first cell types involved in the line of defence against
numerous pathogens. Fibroblasts are widely distributed in
organisms [2] and play an important role in the transition from
innate to adaptive immunity [3,4]. This role is largely a result of
cytokine production [5], most notably IFNb, which was originally
termed fibroblast IFN. As such, fibroblasts are important effectors
of the early innate immune response. Indeed, in a recent study,
non-hematopoietic cells, and fibroblasts in particular, were shown
to mediate protection against an emerging viral infection through
a type I IFN response [6].
As all viruses are thought to make double-stranded RNA
(dsRNA) as a by-product of their replication cycles, this molecule is
a potent producer of type I IFN and as such, is commonly used to
study innate immune responses to virus infection. DsRNA can be
recognized by three different families of pathogen recognition
receptors, the toll-like receptors (TLRs), the retinoic acid inducible
gene I (RIG-I)-like receptors (RLRs) and the nucleotide oligomer-
ization domain-like receptors (NLRs); these bind dsRNA and
initiate cellular signaling pathways [7,8]. The TLRs and RLRs
elicit antiviral pathways involving type I and type III IFNs and
cytokine production, whereas NLRs elicit caspase 1 activation for
IL-1b maturation [7,8]. In fibroblasts, IFN is typically made upon
detection of viral dsRNA by TLR-3 and the RLRs, RIG-I and
melanoma differentiation-associated gene 5 (MDA5). These
pathways converge on NF-kB and IFN regulatory factor 3
(IRF3), which, upon activation, are important for cytokine and
IFNb production. Type I IFN, such as IFNb, signal through the
JAK-STAT pathway, which includes IRF9 as an essential
component. This signaling leads to the induction of IRF7, which
amplifies the cellular antiviral response through the generation of
IFNa species and IFN stimulated genes (ISGs) [8].
In the prototypic antiviral response, IRF3 and early production
of type I IFN and ISGs are arguably the most important events in
combating infection. In humans, inborn errors that impair the
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1production of, or responsiveness to, either of the three classes of
IFN increase susceptibility to mycobacterial and viral infection [9].
Viral infection of mice deficient for IFNb or type I IFN signaling is
typically a lethal event, even under low multiplicity infection
conditions [10–13]. Similarly, in the absence of IRF3, mice are
more susceptible to virus infection due to a 20–50 fold reduction in
type I IFN expression [14]. However, infection of mouse
embryonic fibroblasts (MEFs) deficient for IRF3 with Newcastle
disease virus induced a number of IRF3-independent direct
response genes, including several p200 family proteins [15]. We
have also observed IFN and ISG induction and a subsequent
antiviral response to long dsRNA molecules independent of IRF3
[16]. Alternatively, ISG induction and antiviral protection can be
independent of IFN due to IRF3 binding directly to the promoter
of a subset of ISGs [17]. Despite the presence of multiple
pathways, the type I IFN system dominates the antiviral response
in non-hematopoietic cells such as fibroblasts.
To ensure their success, however, viruses such as the highly
successful human herpes simplex virus (HSV)-1 inactivate IRF3
[18–21] and subvert the type I IFN response [22]. In fact, over 200
anti-IRF3 and anti-IFN mechanisms encoded by diverse viruses
have been identified [23–25]. In general, DNA viruses are
particularly adept at subverting the type I IFN system, particularly
the large DNA viruses that encode multiple immune response
modifiers. Given the importance of IRF3 and type I IFN in
protection against virus infection, it is likely that all viruses encode
mechanisms to disable these proteins. Accordingly, there are
compensatory mechanisms to protect the host in the event that
either of these crucial proteins is compromised. While there have
been numerous studies examining either the IRF3-independent or
the IFN-independent antiviral response, until recently, it was
unknown if the host could be protected if both IRF3 and IFN were
absent.
We have previously observed a protective response against both
DNA and RNA viruses in the absence of IRF3 and IRF9 in
primary MEFs [16]. In response to dsRNA, MEFs deficient for
IRF3 and IRF9 fail to induce other IRFs, IFN or ISGs, suggesting
that the antiviral response observed in these cells is independent of
the type I IFN system [16]. In the absence of IFN and ISGs, there
is approximately 60–90% inhibition of vesicular stomatitis virus
(VSV) and HSV-1 replication following poly I:C stimulation.
Interestingly, the earlier and more potent response occurs against
HSV-1 [16], which is well known for its ability to subvert the host
response in comparison to VSV, which is highly susceptible to the
effects of type I IFN [26–28].
Given the importance of the type I IFN system as the primary
antiviral defence mechanism in non-hematopoietic cells, it is
unknown how these cells protect themselves in the absence of this
system. There are other innate molecules induced by viral
infection that play a role in the host antiviral response. One such
molecule is nitric oxide. Endogenously produced nitric oxide has
many biological functions including smooth muscle relaxation and
neurotransmission [29]. This molecule also plays an important
antimicrobial role against numerous pathogens [30–32]. Although
the antibacterial effects of nitric oxide are well appreciated, nitric
oxide is also effective in the clearance of viruses, particularly DNA
viruses [33–35]; these effects can be independent of IFN and ISGs.
Nitric oxide is synthesized by nitric oxide synthase (NOS) of which
there are three known isoforms, endothelial (e), neuronal (n) and
inducible (i) [29]. In the context of protection against invading
pathogens, the inducible nitric oxide (iNOS) is mainly associated
with phagocytes and other immune cells following induction of
tumor necrosis factor-alpha and IFN-c. Here, we have investigated
the potential role played by nitric oxide in the antiviral response
observed against HSV-1 in MEFs in the absence of IFN
production and signaling. We found that in MEFs, nitric oxide
is made by iNOS in response to dsRNA and plays an important
role in the antiviral state observed in the absence of IRF3 and IFN
production.
Results
Poly I:C induces production of nitric oxide in the absence
of IRF3 and IRF9
We previously showed that IRF3
2/29
2/2MEFs, which fail to
make or respond to type I IFN, induce an antiviral response against
HSV-1 and VSV following treatment with poly I:C. The antiviral
response against HSV-1 in these cells wasfound to occur earlier and
was more potent than the response against VSV [16]. To determine
whetherthis protectionisconferredbyasolublefactor,supernatants
from poly I:C-treated monolayers were transferred to naı ¨ve
monolayers. The transferred supernatants were able to significantly
limit initiation of HSV-1 replication on naı ¨ve monolayers, as
indicated by the decrease in GFP fluorescence following challenge
of monolayers with HSV-1gfp (Figure 1A). We routinely monitor
GFP fluorescence as an indicator of initiation of virus replication
[16]; in IRF3
2/29
2/2MEFs, treatment with poly I:C subsequently
decreases HSV-1 infectious virus production by ,15 fold (data not
shown). To confirm that residual poly I:C was not responsible for
the protective effects, we measured the level of poly I:C in the
supernatants, relative to a standard curve of poly I:C in medium
(Figure 1B). The absorbance of poly I:C-treated supernatants was
only slightly higher than poly I:C deficient (mock) supernatants
(Figure 1C); moreover, poly I:C concentrations within this low
range do not confer resistance to HSV-1 infection in IRF3
2/29
2/
2MEFs [16]. Thus, the soluble factor present within the
supernatants was not residual poly I:C.
As nitric oxide is a soluble factor and an important modulator of
protection against DNA viruses such as HSV-1, we sought to
determine if this molecule is involved in the antiviral response in the
absence of IRF3 and IRF9. It was found via Griess assay, which
measures the nitric oxide by-product nitrite, that these cells make
nitric oxide within 2 hours of stimulation with poly I:C. Nitric oxide
productioninbothwild type(WT)andIRF3
2/29
2/2MEFspeaked
within 5 hours of treatment with poly I:C (Figure 2A).
To confirm that nitric oxide production in IRF3
2/29
2/2 MEFs
decreased initiation of replication of HSV-1, varying concentra-
tions of nitric oxide were added to untreated cells with the use of
the nitric oxide donor, diethylenetriamineNONOate (DETA-NO).
DETA-NO and the control compound diethylenetriamine
(DETA) were added to cells at concentrations ranging from 0–
200 mM. It was determined by Griess assay that DETA-NO used
between 50–100 mM produced nitric oxide to levels similar to
those observed in MEFs after treatment with 8.5 nM poly I:C for
5 hours (Figure 2B). A concentration-dependent effect on
initiation of HSV-1 replication in these cells was observed in both
WT (Figure 2C) and IRF3
2/29
2/2 (Figure 2D) MEFs. Between
50–200 mM DETA-NO was able to limit initiation of HSV-1
replication in WT and IRF3
2/29
2/2 MEFs. At the higher
concentrations, a greater effect of DETA-NO was observed in
IRF3
2/29
2/2MEFs. In each case, the control reagent DETA did
not significantly contribute to nitric oxide production or affect
initiation of HSV-1 replication.
Induction of iNOS is important to the antiviral response
in IRF3
2/29
2/2 MEFs
Nitric oxide can be made by eNOS, nNOS, or iNOS depending
on the stimulus and the cell type. Generally, synthesis has been
dsRNA-Mediated Nitric Oxide Response
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viral components [29]. We used qRT-PCR to measure the levels
of eNOS and iNOS in WT and IRF3
2/29
2/2 MEFs. nNOS was
not determined as this isoform is relatively restricted to neuronal
cells [29]. While eNOS was not detected in either cell type, iNOS
was basally detected in untreated cells to levels of approximately
0.3-fold in comparison to the housekeeping gene, Gapdh (data not
shown). Transcript levels of iNOS increased in both WT and
IRF3
2/29
2/2MEFs upon treatment with poly I:C within 2 hours
(Figure 2E). Induction further increased after 5 hours of poly I:C
treatment, coincident with the timeframe in which protection
against HSV-1 was observed. Levels of iNOS transcript were
reduced to baseline measurements within 7.5 hours of poly I:C
treatment (data not shown).
The classic iNOS inhibitor aminoguanidine hydrochloride
(AMG) was used to determine the involvement of iNOS in the
antiviral response observed against HSV-1 in IRF3
2/29
2/
2MEFs. Based on conflicting reports on the degree of isozyme
selectivity of AMG [36,37], N6-(1-iminoethyl)-L-lysine dihydro-
chloride (L-NIL), a compound more selective in iNOS inhibition
[38], was also used. The efficacy of AMG and L-NIL as inhibitors
of iNOS in poly I:C-treated WT (Figure 3A) and IRF3
2/29
2/2
(Figure 3B) MEFs was determined; there was a statistically
significant reduction in nitric oxide production, as determined
Figure 1. A soluble factor confers resistance to HSV-1 replication in IRF3
2/29
2/2 MEFs. (A) MEFs were directly treated with 8.5 nM poly IC
for 6 hours, or with supernatants from poly IC-treated cells, and subsequently challenged with HSV-1gfp. Initiation of HSV-1 replication, as measured
by GFP fluorescence, is displayed relative to untreated (mock), infected cells, where fluorescence in each experiment was set to 100%. (B) A standard
curve of poly I:C in culture medium was generated. (C) The absorbance of supernatants collected after 6 hours of mock and poly I:C treatment were
collected and absorbance was compared to determine the amount of residual poly I:C within supernatants of treated cells. *, p,0.05, **, p,0.01,
***, p,0.0001. Data are expressed as the mean 6 SEM; n=3.
doi:10.1371/journal.pone.0031688.g001
dsRNA-Mediated Nitric Oxide Response
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e31688Figure 2. Nitric oxide is synthesized by iNOS in response to dsRNA in MEFs. (A) Nitric oxide was produced following treatment with poly I:C
in MEFs as determined by Griess assay. (B) DETA-NO, a nitric oxide donor, induced nitric oxide production in MEFs. Nitric oxide produced via DETA-NO
limited initiation of replication of HSV-1gfp in WT (C) and IRF3
2/29
2/2 (D) MEFs, as measured by GFP fluorescence, where fluorescence levels in mock
treated cultures were set to 100%. DETA alone did not induce nitric oxide production and failed to reduce initiation of HSV-1 replication. (E) The
relative abundance of iNOS mRNA, measured by qRT-PCR, in WT and IRF3
2/29
2/2 MEFs treated with poly I:C was found to be significantly higher in
MEFs deficient for IRF3 and IRF9 after 5 hours of poly I:C treatment in comparison to WT counterparts. Fold changes in transcript levels were
compared relative to the housekeeping gene, Gapdh.* ,p ,0.05, **, p,0.01, ***, p,0.0001. Data are expressed as the mean 6 SEM; n=3.
doi:10.1371/journal.pone.0031688.g002
dsRNA-Mediated Nitric Oxide Response
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the inhibitors. Consistent with our hypothesis that dsRNA-
mediated induction of nitric oxide limits initiation of HSV-1
replication, inhibition of iNOS with either AMG or L-NIL
partially (Figure 3C) or fully (Figure 3D) restored initiation of
HSV-1 replication in WT or IRF3
2/29
2/2MEFs, respectively.
The partial effect observed in WT MEFs is consistent with the
ability of dsRNA to elicit IFN and ISG induction within these cells
[16]. For reference purposes, the effect of IFNb pre-treatment on
limiting initiation of HSV-1 replication is shown (Figure 3C).
Data presented in Figures 1 and 2 show that MEFs treated with
dsRNA produce nitric oxide and that a soluble factor found within
Figure 3. Nitric oxide made by iNOS is involved in the IRF3- and IFN-independent antiviral response. The efficacy of the iNOS inhibitors
AMG and L-NIL to block nitric oxide production was determined by Griess assay following a 5 hour poly I:C treatment of WT (A) and IRF3
2/29
2/2 (B)
MEFs. Initiation of HSV-1gfp replication in WT (C) and IRF3
2/29
2/2 (D) MEFs following treatment with poly I:C in the presence or absence of the iNOS
inhibitors was measured relative to untreated cells, where fluorescence levels were set to 100% in each experiment. WT MEFs, which maintain the
capacity to respond to IFN, are completely protected against HSV challenge following 24 hr pre-treatment with IFNb.* ,p ,0.05, **, p,0.01,
***, p,0.0001. Data are expressed as the mean of three replicates 6 SEM.
doi:10.1371/journal.pone.0031688.g003
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treatment of naı ¨ve cells. To our knowledge, there is no assay that
directly measures nitric oxide within supernatants, in vitro. Thus, to
determine whether nitric oxide or a component(s) of the nitric
oxide pathway is responsible for protection of naı ¨ve monolayers
following supernatant transfer, we transferred supernatants from
cells treated with dsRNA in the presence or absence of the iNOS
inhibitor L-NIL. We observed partial (Figure 4A) or complete
(Figure 4B) restoration of initiation of HSV-1 replication following
transfer of supernatants from cells treated with poly IC in the
presence of L-NIL, relative to transfer of supernatants from cells
treated with poly IC in the absence of an iNOS inhibitor.
Consistent with the ability of WT MEFs to produce IFN and ISGs
in response to dsRNA, only partial restoration of HSV-1
replication initiation was observed in these cells.
NF-kB- and IRF1-mediated induction of iNOS contributes to
protection against HSV-1 in the absence of IRF3 and IRF9
While the transcription factors NF-kB and IRF1 bind to the
iNOS promoter to induce its transcription, these factors can signal
independently of one another [39]. To confirm the role of NF-kB
in the antiviral response observed in the absence of IRF3 and IFN,
NF-kB was blocked using the inhibitor Bay 11-7082, which targets
the phosphorylation of IkBa. Concentrations of Bay 11-7082
ranging from 0 mM–10 mM were tested and 5 mM was determined
to be the optimal concentration to inhibit the nuclear translocation
of NF-kB following treatment of MEFs with poly I:C (Figure 5A).
Inhibition of NF-kB significantly decreased the fold change in
iNOS transcript expression as determined by qRT-PCR in WT
and IRF3
2/29
2/2 MEFs (Figure 5B, 5C). In an antiviral assay,
inhibition of NF-kB with Bay 11-7082 resulted in increased
initiation of HSV-1 replication in poly I:C treated WT and
IRF3
2/29
2/2 MEFs (Figure 5D, 5E); the increase in initiation of
virus replication was found to be significant in IRF3
2/29
2/2
MEFs.
To assess the importance of IRF1 in iNOS induction and the
antiviral response in the absence of IRF3 and IFN, an IRF1-
targeting siRNA was generated. The control siRNA was a
scrambled sequence of the IRF1 siRNA used to account for
nonspecific effects. The efficacy of siRNA on IRF1 transcript levels
Figure 4. A component of the nitric oxide pathway provides antiviral protection in supernatants from dsRNA-treated MEFs. WT (A)
or IRF3
2/29
2/2 (B) MEFs were subjected to the indicated treatment, and initiation of HSV-1gfp replication was subsequently assessed 24 hours
following virus challenge, as a measure of GFP fluorescence. *, p,0.05, **, p,0.01, ***, p,0.0001. Data are expressed as the mean of three replicates
6 SEM, relative to mock treated samples, which were set at 100% in each experiment.
doi:10.1371/journal.pone.0031688.g004
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PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e31688Figure 5. NF-kB contributes to iNOS induction and subsequent antiviral protection against HSV-1 in IRF3
2/29
2/2 MEFs. (A) The
effective concentration of Bay 11-7082 to inhibit NF-kB translocation to the nucleus after treatment with poly I:C was determined. The effect of NF-kB
inhibition by Bay 11-7082 on iNOS mRNA accumulation was measured by qRT-PCR in poly I:C-treated WT (B) and IRF3
2/29
2/2 (C) MEFs. Initiation of
HSV-1gfp replication was quantified in WT (D) and IRF3
2/29
2/2 (E) MEFs following a 5 hour poly I:C treatment in the presence or absence of Bay 11-
7082 and fluorescence compared to untreated monolayers, where fluorescence was set at 100% in each experiment. A 1-way ANOVA with a Tukey
post-test was performed to compare efficacy of a range of NF-kB inhibitor concentrations. An unpaired t-test was performed to compare the antiviral
dsRNA-Mediated Nitric Oxide Response
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significantly reduced in IRF3
2/29
2/2 MEFs treated with IRF1-
specific siRNA compared with cells treated with transfection
reagent DharmaFECT (DF) alone. Although treatment with poly
I:C increased levels of IRF1, these levels were significantly
decreased upon addition of IRF1-targeting siRNA.
Quantitative RT-PCR analysis indicated that inhibition of IRF1
by siRNA significantly reduced iNOS transcript accumulation in
comparison to control siRNA (Figure 6B). Furthermore, initiation
of HSV-1 replication was significantly increased in poly I:C
treated IRF3
2/29
2/2 MEFs in which IRF1 levels were decreased
following siRNA treatment (Figure 6C). Taken together, these
data suggest that both NF-kB and IRF1 contribute to iNOS
induction and subsequent nitric oxide production in poly I:C-
treated IRF3
2/29
2/2MEFs. Moreover, it is likely that these
transcription factors function in additional pathways that contrib-
ute to antiviral activity, including production of type I IFN in WT
MEFs.
Discussion
Fibroblasts are well established as important effectors of the
early innate immune response to pathogens [2–4] due to their
rapid production of IFNb and other cytokines [5]. Many
pathogens, however, such as large DNA viruses, are particularly
adept at subverting the type I IFN system, rendering their
immediate environment IFN system defective. Thus, it is unclear
how effector cells such as fibroblasts respond to specific pathogen
triggers to protect themselves from a viral infection. DsRNA, a by-
product of all viral infections, is a potent inducer of type I IFN,
both as an intracellular and extracellular molecule [40]. Indeed,
early recognition of DNA virus infection, including that of HSV-1,
is mediated in part by dsRNA sensors [41,42]. Although we
previously found that fibroblasts can respond to dsRNA and
protect themselves from subsequent virus infection in the absence
of a type I IFN system, the mechanism of protection was unknown,
as we failed to detect the production of any cytokines or
chemokines [16].
Nitric oxide is an important cellular messenger involved in
diverse physiological and pathological processes. Among its many
properties, nitric oxide has potent antiviral and antibacterial
activity. While macrophages are primary producers of nitric oxide
in response to pathogens, nitric oxide production by dermal skin
fibroblasts and rat embryonic fibroblasts has previously been
shown to play a role in wound healing and host defense in
response to bacterial PAMPs and inflammatory cytokines [43,44].
With regards to the viral PAMP dsRNA, studies have shown
induction of iNOS in human astroglia and bronchial epithelial
cells [45,46]. However, to our knowledge, there have been no
reports of dsRNA eliciting a nitric oxide-mediated antiviral
response in fibroblasts in the absence of type I IFN responses.
We set out to study the mechanism by which an antiviral
response against HSV-1 occurred in the absence of IRF3, IFN and
ISGs, particularly since this response was earlier and more robust
than the cellular response against VSV, a small RNA virus that is
exquisitely sensitive to the host IFN response [16]. We determined
that the antiviral factor responsible for controlling HSV-1
replication was a soluble factor. Coincidentally, nitric oxide acts
as a soluble antiviral factor that is more potent against DNA
viruses in comparison to RNA viruses. We found that nitric oxide
is rapidly produced by MEFs in response to the dsRNA mimetic
poly I:C, and serves to inhibit HSV-1 replication. It is unclear why
the by-products of nitric oxide production appear to decline over
time, as the Griess assay measures nitrite, one of two stable break
down products of nitric oxide. However, recent studies show that
both nitrate and nitrite can be recycled back into the nitric oxide
pathway [47], which may explain this observation. The antiviral
activity of poly I:C-induced nitric oxide was confirmed by the
addition of nitric oxide to MEFs using DETA-NO. While we
cannot directly measure nitric oxide in cellular supernatants, we
found that inhibition of nitric oxide production in MEFs reduced
the antiviral activity within supernatants, suggesting that either
nitric oxide, or a product of the nitric oxide pathway, serves as a
soluble antiviral factor. Of interest, in WT fibroblasts, nitric oxide
is a contributor, albeit minor, to the antiviral response; the ability
to make and respond to type I IFN likely constitutes the major
antiviral activity in these cells. However, in IRF3
2/29
2/2 MEFs,
the nitric oxide pathway appears to be the dominant antiviral
pathway. These data suggest that nitric oxide is an important
antiviral molecule in the absence of IFN, ISGs and other
cytokines.
Previous studies have shown that HSV-1 is susceptible to the
effects of nitric oxide in vivo in mice and rats [33–35]. Although
nitric oxide is synthesized during the host response to pathogen
invasion, its precise role remains unclear. Despite its antiviral
activity, nitric oxide is not always beneficial, as it can promote the
pathogenesis of HSV-1 by damaging cells in host tissues, thus
aiding infection [29,48]. It is unknown at this time whether the
antiviral protection provided by nitric oxide in vivo is exerted in the
form of cytotoxicity as a result of nitrative stress or by an
alternative mechanism. In vitro, treatment of primary fibroblasts
with dsRNA or DETA-NO does not elicit noticeable cytotoxic
effects (data not shown), suggesting that the level of nitric oxide
production that is sufficient to block virus replication is not linked
to cytotoxicity. While it is well known that NO has antiviral
activity, particularly against DNA viruses such as HSV and
vaccinia virus [34,49,50], the mode of action remains to be fully
elucidated. Thiol modification and protein nitrosylation are likely
involved in the antiviral activity of NO [51]. Indeed, viral enzymes
are an important target for NO [52,53]. Although NO displays
antiviral activity against several RNA viruses, including influenza
virus [54], its capacity to induce DNA damage [55] likely explains
its preferential targeting of DNA viruses.
We have found in this study the importance of iNOS as the
enzyme by which nitric oxide is synthesized. This is not surprising,
as iNOS induction in response to virus infection, as well as viral
components, is well known [56–58]. During viral infection, nitric
oxide production by iNOS is induced by cytokines such as IFN-c;
however, virus infection can up-regulate iNOS independently of
such cytokines [29]. While MEFs can respond to IFN-c, they do
not make it in response to poly I:C (data not shown), suggesting
that in fibroblasts, iNOS is induced independent of IFN-c.
The iNOS gene locus has low homology between human, rat
and mouse sequences. As a result, the transcription factors
involved in iNOS induction are species and cell type dependent
[39,59]. For example, regulation of nitric oxide production by
iNOS in humans has been shown to be dependent on AP-1, but a
binding site for this transcription factor is not present on the mouse
iNOS promoter [59]. NF-kB and IRF1 are most commonly
published as regulators of iNOS expression in various species [60–
response in cells that received poly I:C treatment with and without Bay 11-7082; *, p,0.05, **, p,0.01, ***, p,0.0001. Data are expressed as the mean
of three replicates 6 SEM.
doi:10.1371/journal.pone.0031688.g005
dsRNA-Mediated Nitric Oxide Response
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and IRF1 [63,64]. Here we have shown that regulation of iNOS
expression is, at least in part, dependent on both NF-kB and IRF1.
These data are consistent with other reports indicating that both
transcription factors are important for iNOS expression in mice in
response to dsRNA [39,65]. Our data do not exclude, however,
the involvement of other transcription factors or the likelihood that
NF-kB and IRF1 function in contributing to the antiviral response
in another capacity.
Overall, our data show that components of the nitric oxide
pathway serve as alternative antiviral factors in the absence of the
IRF3- and IFN-mediated signaling pathway, and that they also
contribute to the antiviral response in WT cells. While we
conclude that the nitric oxide pathway is important, we cannot
rule out involvement of other pathways or factors. Furthermore,
the factors involved in the antiviral response against VSV after
24 hours of poly I:C pretreatment [16] are still unknown. As levels
of nitric oxide began to decline within 7.5 hours of treatment with
poly I:C, it is unlikely that this pathway is involved in the antiviral
response observed against VSV at this timepoint. These data
emphasize the intricacies of the host response to different
pathogens, and underscore the requirement of the host to have
multiple strategies to counteract the immune evasion properties of
viruses.
Materials and Methods
Ethics statement
Human ethics approval was not required as neither human
subjects nor primary human tissues were utilized. Production of
primary mouse embryonic fibroblasts was completed with full
approval from the McMaster Animal Review Ethics Board. All
work with viruses was completed with full approval from the
McMaster Presidential Biosafety Advisory Committee.
Cells and Viruses
Primary MEFs derived from WT C57Bl/6 and IRF3
2/
2IRF9
2/2 mice [14] were maintained in alpha-minimal essential
medium (MEM) supplemented with 15% fetal bovine serum
(FBS), 100 UNml
21 penicillin, 100 mgNml
21 streptomycin and
2 mM L-glutamine. Experiments were performed with cells at
passages four to eight. All cells were incubated at 37uCi na
humidified 5% CO2 incubator as previously described [16].
Vero cells (ATCC) were maintained in Dulbecco’s modified
Eagle medium (DMEM) supplemented with 5% FBS. HSV-1
(KOS strain) expressing green fluorescent protein (HSV-1gfp) [66]
was propagated on Vero cells. For viral infections, cells were split
and seeded into dishes 24 hours prior to infection. Infections with
HSV-1gfp utilized a multiplicity of infection of 0.1 particle forming
units (PFU) per cell and occurred in serum-free alpha-MEM for
1 hour. This amount of virus is the maximal dose for which signal
saturation in untreated cells does not occur. Following 1 hour of
infection, the viral inoculum was removed and replaced with
DMEM containing 1% methylcellulose. GFP fluorescence inten-
sity was measured on a Typhoon Trio (GE Healthcare) 24 hours
later and quantified using ImageQuant TL software.
Figure 6. IRF1 contributes to iNOS induction in response to
HSV-1 in MEFs. (A) Knockdown of IRF1 by siRNA in IRF3
2/29
2/2 MEFs
in the presence or absence of poly I:C treatment. Fold change in iNOS
mRNA accumulation (B) and initiation of HSV-1gfp replication (C) in
IRF3
2/29
2/2 MEFs treated with poly I:C in the presence or absence of
siRNA against IRF1. *, p,0.05, **, p,0.01, ***, p,0.0001. Data are
expressed as the mean of three replicates 6 SEM.
doi:10.1371/journal.pone.0031688.g006
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Cells were mock-treated, or treated with 8.5 nM poly I:C (GE
Healthcare, Buckinghamshire, UK) in serum-free OptiMEM
medium (Life Technologies) in the presence of 50 mg/ml DEAE-
dextran (Pharmacia) for 1 hour. Full growth medium replaced
OptiMEM for additional indicated amounts of time, unless
otherwise noted. In all experiments, DEAE-dextran was used in
controls not treated with poly I:C to ensure that subsequent
cellular responses were not influenced by the former. It was
previously determined that 8.5 nM poly I:C induces maximum
protection in IRF3
2/29
2/2 MEFs [16]; as such, this concentra-
tion was used to investigate the mediators of the observed antiviral
response.
For IFN treatments, cells were pretreated with 100 U/ml IFNb
(provided by Dr. Brian Lichty, McMaster University) for 24 hours
prior to challenge with HSVgfp.
Supernatant transfer
Supernatants from mock-treated cells and cells treated with
8.5 nM poly I:C for 5 hours were transferred to naı ¨ve IRF3
2/
29
2/2 MEFs and left on for another 5 hours. For experiments
utilizing the iNOS inhibitor L-NIL, please refer to Inhibition of iNOS
section, below. Cells were challenged with HSV-1gfp to determine
if a soluble factor confers resistance to infection in the absence of
both IRF3 and IRF9. Viral replication was quantified 24 hours
post-infection as assessed by GFP fluorescence. To ensure no
residual poly I:C in the transferred supernatants was conferring
resistance to HSV-1 replication, absorbance of the supernatants
was measured. In complete MEF media, poly I:C was serially
diluted 1:5 with concentrations ranging from 2.2610
25–8.5 nM.
This concentration range corresponds with that used in antiviral
assays described previously [16]. A spectrophotometer was used to
determine the absorbance of each concentration to derive a linear
curve. To compare, absorbance of the supernatants at the time of
transfer was also measured.
Measurement of Nitric Oxide Production
MEFs were seeded in 96-well plates to approximately 70%
confluency. After 24 hours, the cells were incubated with poly
I:C for 5 hours as described [16]. Following treatment with poly
I:C, the concentration of nitric oxide in the supernatants of MEF
cultures was assessed by measurement of NO2
2, an oxidized
metabolite of nitric oxide. For this, a Griess reaction was
performed as previously described [67]. Standards were
prepared with known concentrations of NaNO2 (BDH) ranging
from 0–20 mM prepared in alpha-MEM. Griess reagent (Sigma,
USA) was prepared according to the manufacturer’s instructions
and subsequently added to standards and samples. The
absorbance of the supernatants in the plates was read at
550 nm after a 10 minute incubation at room temperature with
Griess reagent.
Nitrite Release
WT and IRF3
2/29
2/2 MEFs were seeded at a confluency of
,80% overnight prior to treatments in 12-well plates for antiviral
assays and in 96-well plates to assess nitrite release via Griess assay.
The cells were treated with 0–200 mM DETA-NO (Sigma, USA)
or with 0–200 mM of the control NONOate, DETA (diethylene-
triamine; Sigma, USA) diluted in complete MEF media for
5 hours. Following treatment, cells were challenged with HSV-1
described earlier in an antiviral assay and viral replication was
quantified as assessed by GFP fluorescence. Fresh DETA or
DETA-NO was added after each medium change.
Quantitative Real Time-PCR (qRT-PCR)
RNA was isolated from cells using TRIzol reagent (Life
Technologies). A random 6-mer primer (0.2 ng) and 50 U of
Superscript II (Life Technologies) were used to reverse transcribe
300 ng of DNase-treated RNA (DNA-free kit, Ambion, Austin,
TX) in a total reaction volume of 20 ml. Subsequently, qRT-PCR
was performed in triplicate using Universal PCR Master Mix and
gene-specific TaqMan primers (Life Technologies) in a total
volume of 25 ml.Data were analyzed via the DDCt method. Gene
expression was normalized to Gapdh, the housekeeping gene, and
expressed as fold change over the mock-treated group (cells treated
with DEAE-dextran alone). TaqMan specific primers used in this
study include iNOS (Mm00440502_m1), IRF1 (Mm00515191_
m1) and Gapdh (Mm99999915_g1).
Inhibition of iNOS
The iNOS inhibitors AMG and L-NIL (Sigma, USA), were
diluted in complete medium to a final in-well concentration of
10 mM. To investigate the efficacy of the iNOS inhibitors, cells
were pretreated for 2 hours with iNOS inhibitors prior to a 5 hour
treatment with poly I:C. RNA was then collected using TRIzol
and prepared for qRT-PCR as described above. Expression of
iNOS transcript levels both with and without inhibitor were
compared using TaqMan specific primers to determine efficacy of
each of the iNOS inhibitors used.
To investigate the role of iNOS in the antiviral response, cells
seeded the previous day in 12-well plates to 80% confluency were
treated as described above. Cells were subsequently challenged
with HSV-1gfp as indicated previously.
NF-kB Inhibitor Preparation
The NF-kB inhibitor Bay 11-7082 (EMD, Gibbstown, NJ) was
prepared in 1% DMSO, and used at concentrations ranging from
1–10 mM. Cells were incubated with this compound for 0.5 hours
prior to mock and poly I:C treatments. DMSO was included in
mock- and poly I:C-treatments.
Immunofluorescence Microscopy
To determine the efficacy of Bay 11-7082 in inhibition of NF-
kB in IRF3
2/29
2/2 MEFs, cells were seeded on glass coverslips
overnight at 60% confluency. Cells were either mock- or poly I:C-
treated with and without Bay 11-7082. Following 5 hours of
treatment, cells were fixed with 10% formalin and subsequently
permeabilized with 0.1% Triton X-100 diluted in 16 PBS for
10 minutes each. An overnight blocking step at 4uC followed in
16PBS with 2% goat serum. A 1:200 dilution of NF-kB p65
antibody (Santa Cruz Biotechnology, CA, USA) was added to the
coverslips for 1 hour at room temperature. A secondary anti-
rabbit IgG Alexafluor 488 antibody diluted 1:1000 (Life
Technologies) was hybridized for 1 hour at room temperature.
Nuclei were stained with Hoescht dye diluted 1:10000 for
10 minutes. All antibody and Hoescht dilutions were in 16PBS
with 2% goat serum. Images were taken and analyzed using a
Leica DM IRE2 inverted microscope with Openlab software
(Improvision). Nuclear translocation of cells that received poly I:C
and the inhibitor was plotted as a percent of untreated cells (mock-
treated) corresponding to each dilution of Bay 11-7082.
IRF1 siRNA
An oligonucleotide specific for IRF1, (59-CAGACATCGAG-
GAAGTGAAGGATCA-39) and a scrambled sequence (scr; 59-
CAGTAGCGAAGGAGTAAGGACATCA-39) were designed
(Thermo Scientific). The scrambled sequence was used to account
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were tested so as not to match any known murine gene (other than
murine IRF1) sequences by using NCBI nucleotide BLAST at
http://www.ncbi.nlm.nih.gov/BLAST/. Transfection was per-
formed according to the manufacturer’s protocol. IRF1 siRNA
and scrambled siRNA were used at a concentration of 50 mM.
IRF1 gene expression following knockdown was quantified by
qRT-PCR.
Statistical Analyses
Data are represented as the mean of three replicates 6 standard
error of the mean (SEM). A one-way ANOVA with a Tukey post-
test was used to compare the means of 4 concentrations of Bay 11-
7082 in inhibition of NF-kB nuclear translocation. An unpaired t-
test was used to compare the means of two groups where
indicated. All analyses were performed using GraphPad Prism 5.0
software.
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